We are a global biopharmaceutical company developing novel therapeutics and drug delivery technologies to deliver life-changing treatment for patients with unmet medical needs.

Our goal is to develop immunotherapies targeting proteins that are central players driving uncontrolled activation of the complement cascade, contributing to a broad array of complement-dependent autoimmune and inflammatory diseases.

We aim to create the first-in-class C3 immunotherapies for several chronic inflammatory diseases including those within haematology, ophthalmology, and nephrology as well as patients with severe COVID-19.

As we transition from a clinical-stage to a commercial biopharmaceutical company, we believe our drugs have the potential to improve on current treatment options or provide a treatment option for certain rare diseases where currently none exists.

If you wish to find more information regarding our science, product pipeline, or ongoing clinical trials, please follow the link www.apellis.com.